Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human papillomavirus vaccines.

Margaret A Stanley1

  • 1Department of Pathology, University of Cambridge, UK. mas@mole.bio.cam.ac.uk

Current Opinion in Molecular Therapeutics
|March 9, 2002
PubMed
Summary

Human papillomavirus (HPV) vaccines, including virus-like particles (VLPs) and other approaches, show promise. While safe and immunogenic in early trials, their efficacy for preventing or treating HPV infections requires further investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.

Vaccine·2024
Same author

Possible Reactivation of Latent Anal Human Papillomavirus Associated with Markers of Immune Dysfunction in Gay and Bisexual Men.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2022
Same author

Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?

Preventive medicine·2021
Same author

IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity".

Papillomavirus research (Amsterdam, Netherlands)·2020
Same author

Carcinogenic human papillomavirus infection.

Nature reviews. Disease primers·2016
Same author

Alternative dosage schedules with HPV virus-like particle vaccines.

Expert review of vaccines·2014

Area of Science:

  • Vaccinology
  • Virology
  • Immunology

Background:

  • Genital human papillomaviruses (HPVs) are a significant public health concern.
  • Current vaccine development focuses on subunit vaccines, particularly virus-like particles (VLPs) based on the L1 major capsid protein.

Purpose of the Study:

  • To review the current status and potential of various HPV vaccine candidates.
  • To assess the immunogenicity, safety, and potential efficacy of different vaccine platforms.

Main Methods:

  • Evaluation of phase I and II clinical trial data for L1 VLP vaccines.
  • Review of preclinical and early clinical data for polynucleotide, recombinant viral, peptide, protein, and dendritic cell vaccines targeting HPV oncoproteins (E6 and E7).

Main Results:

  • L1 VLP vaccines are immunogenic and safe in early clinical trials, but efficacy data are pending.
  • VLPs induce robust cell-mediated and humoral immune responses.
  • Chimeric VLPs and vaccines targeting E6/E7 oncoproteins show therapeutic and prophylactic potential in animal models, with some demonstrating immunogenicity but not efficacy in limited human trials.

Conclusions:

  • L1 VLP vaccines are a leading candidate for HPV prevention.
  • Therapeutic vaccines targeting HPV oncoproteins warrant further investigation for established infections.
  • Continued research is crucial to establish the efficacy of these diverse HPV vaccine strategies.

Related Experiment Videos